Bin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bin Wu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Xueguan Lu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Clinical Research Center for Radiation Oncology, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
41 shared publications - Chaosu Hu
Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
40 shared publications - Changming Zhou
Department of Respiratory Disease, The First Affiliated Hospital of Bengbu Medical College , Bengbu , China
39 shared publications - Dan Ou
Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
39 shared publications - Dongmei Ji
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
39 shared publications - Hongmei Ying
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University Shanghai Cancer Center, Shanghai, China
39 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101181
Validation of the 9th edition cTNM classification for HPV-positive oropharyngeal carcinoma in a non-endemic Chinese cohort
- 1 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101181
Open AccessValidation of the 9th edition cTNM classification for HPV-positive oropharyngeal carcinoma in a non-endemic Chinese cohort
- Open Access
- 6 August 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (10) , 1-13
Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
Patients with recurrent or metastatic head and neck cancers (R/M HNCs) are prone to developing resistance after immunotherapy. This retrospective real-world study aims to investigate whether the addition of anlotinib can reverse resistance to PD-1 inhibitors (PD-1i) and evaluate the efficacy and safety of this combination in R/M HNCs. Main outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. Potential biomarkers included PD-L1 expression, lipid index, and genomic profiling. Twenty-one patients with R/M HNCs were included, including 11 nasopharyngeal carcinoma (NPC), five head and neck squamous cell carcinoma (HNSCC), three salivary gland cancers (SGC), and two nasal cavity or paranasal sinus cancers (NC/PNC). Among all patients, ORR was 47.6% (95% CI: 28.6–66.7), with 2 (9.5%) complete response; DCR was 100%. At the median follow-up of 17.1 months, the median PFS and OS were 14.3 months (95% CI: 5.9-NR) and 16.7 months (95% CI:8.4-NR), respectively. The median DOR was 11.2 months (95% CI: 10.1-NR). As per different diseases, the ORR was 45.5% for NPC, 60.0% for HNSCC, 66.7% for SGC, and 50.0% for NC/PNC. Most treatment-related adverse events (TRAEs) were grade 1 or 2 (88.9%). The most common grades 3–4 TRAE was hypertension (28.6%), and two treatment-related deaths occurred due to bleeding. Therefore, adding anlotinib to the original PD-1i could reverse PD-1 blockade resistance, with a favorable response rate, prolonged survival, and acceptable toxicity, indicating the potential as a second-line and subsequent therapy choice in R/M HNCs.
- 6 August 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (10) , 1-13
Open AccessAnlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
Patients with recurrent or metastatic head and neck cancers (R/M HNCs) are prone to developing resistance after immunotherapy. This retrospective real-world study aims to investigate whether the addition of anlotinib can reverse resistance to PD-1 inhibitors (PD-1i) and evaluate the efficacy and safety of this combination in R/M HNCs. Main outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. Potential biomarkers included PD-L1 expression, lipid index, and genomic profiling. Twenty-one patients with R/M HNCs were included, including 11 nasopharyngeal carcinoma (NPC), five head and neck squamous cell carcinoma (HNSCC), three salivary gland cancers (SGC), and two nasal cavity or paranasal sinus cancers (NC/PNC). Among all patients, ORR was 47.6% (95% CI: 28.6–66.7), with 2 (9.5%) complete response; DCR was 100%. At the median follow-up of 17.1 months, the median PFS and OS were 14.3 months (95% CI: 5.9-NR) and 16.7 months (95% CI:8.4-NR), respectively. The median DOR was 11.2 months (95% CI: 10.1-NR). As per different diseases, the ORR was 45.5% for NPC, 60.0% for HNSCC, 66.7% for SGC, and 50.0% for NC/PNC. Most treatment-related adverse events (TRAEs) were grade 1 or 2 (88.9%). The most common grades 3–4 TRAE was hypertension (28.6%), and two treatment-related deaths occurred due to bleeding. Therefore, adding anlotinib to the original PD-1i could reverse PD-1 blockade resistance, with a favorable response rate, prolonged survival, and acceptable toxicity, indicating the potential as a second-line and subsequent therapy choice in R/M HNCs.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
The Differential Expression of Various Genes between the Resistant and Sensitive Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Details of radiotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Overall response rate of induction chemoimmunotherapy (N=27)
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Changes of quality of life at different timepoints
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Changes of quality of life at different timepoints
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups